Bulletin
Investor Alert

press release

Nov. 10, 2021, 6:31 a.m. EST

Adagio Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov 10, 2021 (GLOBE NEWSWIRE via COMTEX) -- WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., /zigman2/quotes/228559245/composite ADGI +10.37% a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced participation in the following upcoming investor conferences:

  • Stifel 2021 Virtual Healthcare Conference: Management will participate in a fireside chat discussion on Tuesday, November 16, 2021, at 8:40 a.m. ET.

  • Jefferies 2021 Virtual London Healthcare Conference: Management will participate in a fireside chat discussion during the conference, being held November 16-19, 2021. The fireside chat will be available to registered participants on-demand between 8:00 a.m. GMT on November 18, 2021, and 5:00 p.m. GMT on November 19, 2021.

  • Evercore ISI 4th Annual HealthconX Conference: Management will participate in a fireside chat discussion on Wednesday, December 1, 2021, at 2:40 p.m. ET.

The webcasts will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 60 days following the presentations.

About Adagio TherapeuticsAdagio /zigman2/quotes/228559245/composite ADGI +10.37% is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company's portfolio of antibodies has been optimized using Adimab's industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio's portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring broad accessibility to people around the world. For more information, please visit www.adagiotx.com .

Contacts:Media Contact:Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

COMTEX_396659073/2471/2021-11-10T06:30:49

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/228559245/composite
US : U.S.: Nasdaq
$ 2.98
+0.28 +10.37%
Volume: 887,868
May 27, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$296.23 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/228559245/composite
US : U.S.: Nasdaq
$ 2.98
+0.28 +10.37%
Volume: 887,868
May 27, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$296.23 million
Rev. per Employee
N/A
loading...

Partner Center

Link to MarketWatch's Slice.